Related Experiment Video
Updated: Dec 26, 2025
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia
Xia Lin1,2, Qing Ling1,2, Yunfei Lv1,2
1Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
Background:
The interest in plasma biomarkers has increased recently. Plasma exosome-derived microRNA-532 is aberrantly expressed in a variety of human cancers and has the prognostic value in many solid tumors. However, the prognostic impact of the expression value on AML remains unclear.
Objective:
The aim of this study is to investigate the prognostic value of exosome-derived microRNA-532 in AML patients.
Methods:
We performed the real-time PCR to quantify exosome-derived microRNA-532 in plasma of 198 AML patients. To assess the prognostic value, we performed Cox regression analyses in the context of well-established clinical and molecular markers. Cellular metabolic profile was conducted to help us understand the biological insight of its expression.
Results:
The expression level was not associated with white blood cell counts, age, FAB subtypes, cytogenetic risk groups and genes of FLT3-ITD, NPM1, CEBPA and DNMT3A mutations. Interestingly, high expressers had a favorable overall survival in the univariate analysis. This prognostic value was testified in the multivariate analysis. Moreover, up-regulation of miR-532 was negatively associated with cellular energy like fructose and glutamine.
Conclusion:
We found plasma exosome-derived microRNA-532 can be used as a novel survival predictor for acute myeloid leukemia.
Insights
Plasma exosome-derived microRNA-532 shows prognostic value in acute myeloid leukemia (AML). High levels of this microRNA predict favorable overall survival in AML patients, offering a novel biomarker for the disease.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Plasma exosome-derived microRNAs are emerging biomarkers in various cancers.
- MicroRNA-532 (miR-532) shows aberrant expression and prognostic value in solid tumors.
- The prognostic significance of exosomal miR-532 in acute myeloid leukemia (AML) is not well-established.
Purpose of the Study:
- To investigate the prognostic value of exosome-derived microRNA-532 in plasma of acute myeloid leukemia patients.
- To determine if exosomal miR-532 can serve as a predictive biomarker for AML survival.
Main Methods:
- Quantification of plasma exosome-derived microRNA-532 using real-time PCR in 198 AML patients.
- Prognostic value assessment via Cox regression analyses, incorporating clinical and molecular markers.
- Exploration of biological insights through cellular metabolic profiling.
Main Results:
- Exosomal miR-532 expression was not correlated with standard AML clinical or molecular features.
- High expression levels of exosomal miR-532 were associated with favorable overall survival in both univariate and multivariate analyses.
- Upregulation of miR-532 showed a negative association with cellular energy metabolites like fructose and glutamine.
Conclusions:
- Plasma exosome-derived microRNA-532 is a novel and valuable survival predictor for acute myeloid leukemia.
- Exosomal miR-532 represents a promising non-invasive biomarker for AML prognosis.
